Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0010200 (cough)
 23,843 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This paper reports the results of the effects of the emergent vaccination with DTP vaccine to control the outbreak of pertussis. Objects of observation were 4-6 years old children of kindergarten having pertussis vaccination and exposed history. The children were at random divided into two groups: 76 children were vaccinated with DTP vaccine and 72 children were inoculated with placebo. The results of observation: there was no strong and abnormal reaction in the vaccinated children; two weeks and three months after emergent vaccination with DTP vaccine, GMT antibody of pertussis were increased 18.14 and 4.73 times more than before vaccination respectively. There were no differences of the attack rates average days from vaccination to onset, average days of cough (P greater than 0.2) within 21 days after vaccination between the two groups. The protection rate was 62.11% three months after vaccination. The results showed that the emergent vaccination with DTP to control the outbreak of pertussis was safe and effective.
 ...
PMID:[The effect of the emergent vaccination using DTP vaccine to control the outbreak of pertussis]. 227 84

Adenovirus serotypes 4 (ADV-4) and 7 (ADV-7) are important causes of febrile acute respiratory disease (ARD) in US military recruits. Previously licensed vaccines, which effectively controlled adenovirus-associated ARD, are no longer available. In the Fall of 2004 we conducted this Phase 1 randomized, double-blind, placebo-controlled trial of the live, oral ADV-4 and ADV-7 vaccines made by a new manufacturer to assess their safety and immunogenicity. The adenovirus vaccines were administered orally together in a single dose to thirty subjects. Twenty eight additional subjects received placebo. Subjects were then observed for 8 weeks. The most commonly reported adverse events were nasal congestion (33%), cough (33%), sore throat (27%), headache (20%), abdominal pain (17%), arthralgia (13%), nausea (13%) and diarrhea (13%). None of these rates differed significantly from placebo. The duration of vaccine virus fecal shedding was 7-21 days. Seventy three percent of vaccine recipients seroconverted to ADV-4 (GMT 23.3) while 63% seroconverted to ADV-7 (GMT 51.1) by Day 28. The new ADV-4 and ADV-7 vaccines were safe and induced a good immune response in the study population. Expanded trials for safety and efficacy are in progress.
 ...
PMID:A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. 1844 11